OVERVIEW

The Evolution of Incretin Therapy: The Potential Role of GIP/GLP-1 Receptor Agonists in Treating Patients with Obesity and T2DM is organized by Med Learning Group.

Release Date: May 31, 2022
Expiration Date: May 31, 2023

Program Overview:
This CME program has been designed for endocrinologists who treat patients with type 2 diabetes. It aims to help learners evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes, and to increase knowledge of the mechanism of emerging GIP/GLP-1 receptor agonists and their impact on glycemic outcomes and body weight in order to advantageously integrate them into clinical practice when available.

Learning Objectives:
• Evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes
• Explain the mechanism of action of GIP/GLP-1 receptor agonists
• Assess the potential role of GIP/GLP-1 receptor agonists in the treatment of patients with T2DM and obesity